Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00202644
Status:
COMPLETED
Last Update Posted:
2021-06-02
First Post:
2005-09-12
Brief Title:
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
A Phase IIIb Randomized Open Label Study to Compare the Safety Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Essential thrombocythaemia is a disorder of bone marrow which causes too many platelets to be produced Platelets are small cells carried around in the blood which help form blood clots When patients have too many platelets there is a risk of blood clots forming unnecessarily and excessive bleeding The aim of this study is to gain additional information on the safety profile of Anagrelide Xagridr and Hydroxyurea also known as hydroxycarbamide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-004061-15 | EUDRACT_NUMBER | None | None |